Hematopoietic Stem Cell Transplantation for Sickle Cell Anemia with Busulfan-Based Reduced Intensity Conditioning: Cure and Fertility  by Dennison, David et al.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S279eS312 S285351
How Much Is Enough? Ethical Consideration for the
Depletion of Large Public Cord Blood Units (CBU)
Jason Dehn 1, Jane Kempenich 1, Michael Boo 2,
Michelle Setterholm 1. 1 Scientiﬁc Services, National Marrow
Donor Program, Minneapolis, MN; 2 Business Development,
National Marrow Donor Program, Minneapolis, MN
Background: The Be The Match Registry provides
access to over 230,000 CBU with a median pre-freeze
Total Nucleated Cell (TNC) count of 105 x 10^7 TNC.
Prior studies have established an acceptable dose
threshold of at least 2.5 x 10^7 for the treatment of
hematological malignancies. Pediatric patients often only
require a single CBU to achieve suitable cell dose for
transplant (Tx) and some have received cell doses per
patient weight in excess of 20 x 10^7 TNC/kg. Mean-
while adults may require multiple units to achieve the
recommended minimal dose. This study evaluated
whether CBU Tx in peds achieving a cell dose >20 x
10^7 TNC/kg deplete a unit that may be suitable for an
adult patient when another potentially acceptable unit is
available for the child.
Methods: We identiﬁed 74 single CBU Tx of patients age
0-12 years old, facilitated through the Be The Match
Registry from Sept 2009 to Aug 2012 with a Tx cell dose
>20 x 10^7 TNC/kg. The CBU searches were reviewed to
determine whether another suitable CBU (10-20 x 10^7
TNC/kg and equivalent or better low resolution HLA-A, B,
C, high resolution -DRB1) was available for that patient. A
TNC threshold for CBU suitability for a potential adult
patient of 178 x 10^7 was established based on the
historical median weight of 71kg for adult CBU Tx
recipients.
Results: Of the 74 Tx evaluated, 58 (78%) units had
a minimum TNC of 178 x 10^7 (range 178-452), large enough
for the median weight adult patient. In 48 of the 58 cases
a suitable CBUwith 10-20 TNC/kgwas available on the search
with an equivalent or better HLA match and 23% of the time
the lower TNC CBU was a better HLA match. If the lower TNC
CBUs had been selected for this cohort, the median cell dose
would decrease from 28.7 to 11.5 TNC/kg.
Conclusions: The number of CBU in the registry that
meet the median adult patient dose of 178 x 10^7 TNC is
16,494 (7%) CBU compared to 234,292 available for peds
Tx. Transplant practice is often to take the largest CBU
available for a patient, with consideration of HLA match
differing between centers. This study shows that CBU
used in Tx for children can exceed 20 x 10^7 TNC/kg.
These CBU have a large TNC and could be suitable for
adolescent or adult single cord transplantation. Although
74 CBU Tx correspond to a small proportion of total peds
(age 12 and under) single CBU Tx during this timeframe
(n¼951), these units may offer the only opportunity for
an adult patient. With a limited number of CBUs
achieving high TNC available for adult patients, consid-
eration of the ethics of providing a young patient with an
adequate TNC CBU (e.g. 10-20 x 10^7 TNC/kg) vs the
largest TNC CBU will continue to confront the commu-
nity. Centers should consider selecting a CBU with
smaller, yet still substantial cell dose, particularly when
it's a better HLA match. Future outcomes research is
needed to elucidate the optimal TNC or identify
a maximum threshold recommendation for guidance in
CBU Tx in small children prior to a policy being imple-
mented.352
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Hematopoietic stem cell transplantation (HSCT) is
increasingly being used in the management of patients
with sickle cell disease (SCD). Although cure remains the
fundamental goal, preservation of fertility in this young
patient population is an important consideration. While it
is known that standard busulfan-based myeloablative
conditioning uniformly causes permanent gonadal
dysfunction, complete graft rejection is a serious drawback
in busulfan-free exclusively immunosuppressive-based
preparative regimens with ﬂudarabine and cyclophospha-
mide alone. Therefore if busulfan is to remain a central
part of the conditioning, a signiﬁcant dose reduction may
be necessary to cure and yet preserve fertility. The subse-
quent successful outcome and preservation of fertility in
two young adults transplanted in our center with
busulfan-based targeted-dose reduced intensity condi-
tioning (RIC) for paroxysmal nocturnal hemoglobinuria,
prompted us to consider this regimen in SCD. Between
September 2008 and April 2012, 16 patients with SCD
underwent HSCT in the Sultan Qaboos University Hospital,
Oman. The conditioning regimen consisted of ﬂudarabine
30mg/m2/day for 6 days, two days of targeted-dose
intravenous busulfan (target Css 850ng/ml) and rabbit anti-
thymocyte globulin (10mg/kg/day for 4 days beginning on
day minus 4). The median age was 18 yrs (range 9-40 yrs)
and transplant indications were recurrent vaso-occlusive
crises, acute chest syndrome and cerebrovascular events.
There were nine males and seven female patients. The
stem cell source was peripheral blood in 14 (88%) and bone
marrow in 2 patients (12%). Fourteen patients (88%) are
considered cured with a median follow up of 24 months
(6-49 mths). Nine (64%) of these patients have complete
donor chimerism (DC) while ﬁve (36%) patients have stable
mixed chimerism ranging from 67-90%. Two patients (12%)
rejected their grafts with rapid loss of DC by 6 months and
are alive with their original SCA manifestations. Acute graft
versus host disease (Grade III) occurred in only one patient
and resolved with therapy. Of the 6 post pubertal female
patients, only one has resumed normal periods following
the transplant. The ﬁve others (median age 24yrs, range
16-27yrs) developed amenorrhea post transplant with high
FSH and LH levels and have been started on hormonal
replacement therapy. No tests of gonadal function in the
male patients are available. Busulfan-based RIC HSCT is
curative and appears to be safe even in older patients with
SCA but gonadal damage continues to remain a long term
complication. There may be a window of opportunity to
further reduce busulfan exposure in an attempt to preserve
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induce immune tolerance may also be required to mini-
mize rejection.Figure 1. Recovery of T cell subsets after matched and mismatched ASCT353
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Allogeneic stem-cell transplantation (ASCT) is curative for
many malignant and nonmalignant hematological disorders.
We aimed to study reconstitution of lymphocyte subsets
after matched and mismatched transplantation.
Lymphocyte subsets were evaluated by ﬂow cytometry at
1,3,6 and 12 months (mo) post-ASCT. Lymphocyte recovery
was determined using means at each time point and group
differences assessed using analysis of variance.Time-to-
event outcome were estimated by Kaplan-Meier survival
curves and the log-rank test was used to evaluate differences
between groups. 100 patients (pts) were included in the
study: 25 received a matched sibling (MSD), 20 pts
a matched unrelated donor ASCT 10/10 (MUD), 18 pts a 9/10
MUD, 9 pts a T cell depleted haploidentical (TCD haplo), and
28 a T cell replete haploidentical transplant (TCR haplo). 53
pts received bone marrow and 47 peripheral blood stem
cells. Most patients were treated for acute leukemia (AML 41,
ALL 23), 16 MDS, 6 CML, 4 CLL, 5 lymphoma. Median age was
43 years (range: 20-71). Median follow-up was 13.6 mo. 60
pts were alive and disease-free at last follow-up and 28 pts
died 75% of relapse. Non-relapse mortality (NRM) was 6% for
the entire cohort.
Overall, alive pts (vs. who died) had higher mean CD3
(615 vs. 349, P ¼ .03 on day 90), CD8 (427 vs. 187, P ¼ .03 on
day 90), CD4 (391 vs. 54, P¼ .01, on day 365), and lowermean
CD56 cells (178 vs 300, P¼ .01, on day 30) post ASCT. Pts who
progressed (vs. did not), had lower 1 year mean CD4 (123 vs.
394, P ¼ .02), lower mean CD3 (359 vs. 1147,P ¼ .06), with no
differences in CD8, NK, and CD45RA cells. NRM was associ-
ated with higher mean NK counts at 6 months (499 vs. 188,
P ¼ .01) and with lower mean CD3 at day 90 (184 vs. 557,
P ¼ .07). T-cell recovery occurred most rapidly in MSD
transplants (Figure1), and interestingly, higher CD4CD25 cell
numbers recovered early and most rapidly in the MSD
transplants, which may partly explain a lower incidence of
GVHD in this group. Overall, TCR haplos had a similar pattern
of T-cell recovery and outcomes as 10/10 MUDs (Figure1). No
signiﬁcant differences in T cell subsets found between these
two groups for CD3, CD4, CD8, CD45RA and CD4CD25 at any
time-point. TCD haplos had most impaired T-cell reconsti-
tution and outcomes (Fig. 1), characterized by early NK cell
and delayed CD3, CD4, CD8 recovery. Interestingly, pts
surviving 6-9 months post-transplant recovered CD3, C4,
CD8 cells; however, naïve T-cell recovery was impaired for
more than >1 year post-transplant, suggesting that T cellrecovery comes predominantly from the memory T cell
compartment.
In conclusion, recovery of lymphocyte subsets may
vary widely with the type of transplant, may correlate
with outcomes, and should be further explored post-
transplant.354
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Combined renal and hematopoietic cell transplantation
(HCT) protocols have successfully induced allograft tolerance
despite loss of chimerism in patients; however, the mecha-
nism remains unclear. Using a miniature swine model with
demonstrated clinical relevance, we assessed immune
responses following HCT in ten recipients that lost chime-
rism. All animals received 30 days of cyclosporine (CyA) with
taper until day 45; low-dose total body irradiation (100cGy
TBI) and T cell depletion using a CD3 immunotoxin (pCD3-
IT). Six animals received mobilized donor cells and 4 animals
received unmobilized cells. Control animals received allo-
geneic cells without any immunosuppression. Cellular
responses were assessed bymixed lymphocyte reactivity and
cell mediated lympholysis assays. Donor speciﬁc antibody
was assessed by ﬂow cytometry and complement mediated
cytotoxicity assays.
Following loss of chimerism, anti-donor cellular prolifer-
ative and cytotoxic responses returned without alloantibody.
Alloantibody responses were not induced even after a second
exposure to donor cells intravenously without immunosup-
pression (n¼10) or following donor skin graft rejection
(n¼3). Attempts to further immunize some of these animals
(n¼6) with multiple subcutaneous injections of donor cells
with or without complete Freund's adjuvant also failed to
induce donor speciﬁc antibody. In contrast, control animals
exposed to donor cells without conditioning had sustained
